Sonendo, INC

Sonendo, Inc. has entered into an amendment to its credit agreement, deferring and waiving certain amortization payments contingent upon successful equity financings.

Sonendo, Inc. announced a significant reduction in operating losses and free cash flow burn for the third quarter of 2024, despite a slight decrease in revenue.

Sonendo, Inc. was not the winning bidder in the bankruptcy auction for Biolase assets and will receive a break-up fee and expense reimbursement.

Sonendo, Inc. has executed a 1-for-200 reverse stock split, effective October 18, 2024, to consolidate its shares and potentially improve its stock price.

Sonendo reports preliminary Q3 2024 revenue between $7.9 and $8.0 million and increases its full-year 2024 revenue guidance.

Sonendo, Inc. has entered into an asset purchase agreement to acquire certain assets of Biolase, Inc. and its subsidiaries related to dental laser systems for $14 million in cash, assumption of liabilities, and the value of a pending litigation.

Sonendo Inc. reported its Q3 2024 results, showing a decrease in revenue but improved gross margins, while also navigating significant financial challenges and strategic changes including a reverse stock split and delisting from the NYSE.

Sonendo Inc. reported a decrease in revenue but improved gross margins for the second quarter of 2024, while navigating delisting from the NYSE and ongoing financial challenges.

Sonendo, Inc. announced its first quarter 2024 results, which included the divestiture of its software segment and a renegotiated loan agreement, while also reporting a net loss from continuing operations.

Sonendo, Inc. reports its 2024 financial results, including a net loss of $33.5 million, and announces the suspension of its SEC reporting obligations.

Sonendo, Inc. reports a net loss of $60.9 million on revenue of $43.9 million for 2023, while divesting its software segment to focus on its core medical technology business.

John P. McGaugh, Sr. VP of Operations at Sonendo, Inc., was granted 500,000 Restricted Stock Units (RSUs) on September 17, 2024.

Chief Financial Officer of Sonendo, Inc., John J. Bostjancic, reports acquiring 600,000 shares of common stock through a grant of Restricted Stock Units.

Sonendo's CEO, Bjarne Bergheim, was granted 1,600,000 Restricted Stock Units (RSUs) on September 17, 2024, which will vest quarterly over four years.

Director Pudipeddi Vamsi Mohan Raj of Sonendo, Inc. was granted 200,000 Restricted Stock Units (RSUs) on September 17, 2024.

Director Carolyn Beaver of Sonendo, Inc. was granted 200,000 Restricted Stock Units (RSUs) on September 17, 2024, which will vest within one year or at the 2025 annual meeting.

Director Anthony P. Bihl III of Sonendo, Inc. [SONX] received 200,000 Restricted Stock Units (RSUs) on September 17, 2024.

Sonendo, Inc. will hold its annual meeting on June 10, 2024, and is seeking stockholder approval for several proposals, including the election of directors, ratification of the auditor, and a potential reverse stock split.

Sonendo, Inc. will hold its 2024 Annual Meeting of Stockholders virtually on June 10, 2024, to vote on director elections, ratification of the accounting firm, and a proposed reverse stock split.

First Wilshire Securities Management, Inc. reports a 0.0% beneficial ownership in Sonendo Inc. common stock, indicating a full divestment.

First Wilshire Securities Management, Inc. has reported a 7.9% beneficial ownership stake in Sonendo Inc. as of December 31, 2024, held for ordinary course investment purposes.